Anxel is indicated for the management of the acute condition of agitation in adults who have a diagnosis of schizophrenia or bipolar I or II disorder. The administration of Anxel helps to achieve calming in patients. The effect in controlling the acute episode of agitation may begin as early as twenty minutes following dosing.

• Quick Facts: Anxel Uses
  • Acute treatment for agitation associated with schizophrenia in adults.
  • Acute treatment for agitation associated with bipolar I or II disorder in adults.
  • Aids in achieving calming during acute episodes.

Controlling agitation is an essential objective of treatment, as it may help avoid the need for coercive measures such as physical restraint. Anxel is a self-administered therapy and is used for acute episodes.

Official Eligibility Profile

Determining who can and cannot use any prescription medicine, including Anxel, relies strictly on the official Prescribing Information (US FDA) or Summary of Product Characteristics (EU EMA). These regulatory documents provide mandated rules for use based on clinical data, ensuring patient safety.

Based on available authoritative regulatory documents for the specific brand name Anxel, a complete, verifiable eligibility profile could not be established. Patients must always consult the full, current official labeling or speak with a healthcare provider who can review the complete prescribing information.

Population Status	Regulatory Classification Rule
Populations Contraindicated	Not established in available public regulatory summaries for Anxel.
Age-related Eligibility	Not established in available public regulatory summaries for Anxel.
Condition-specific Limitations	Not established in available public regulatory summaries for Anxel.
Pregnancy/Lactation	Not established as an eligibility status in available regulatory summaries for Anxel.

All decisions on starting or continuing treatment with Anxel must be made by a healthcare professional after thorough review of the complete, official label, including all warnings, precautions, and contraindications. This ensures the medicine is appropriate for the individual's specific health status and medical history.

Anxel is a trade name for a drug containing lacosamide, an anti-epileptic medicine. Its use alongside other substances may result in drug-drug interactions that alter the effect of Anxel or the other medications. Such interactions can be classified based on whether they affect drug levels (pharmacokinetic) or combined clinical actions (pharmacodynamic).

---

Anxel Interactions with other medicines and products

Key Interaction Classes

Category	Interacting Products/Classes	Potential Effect and Mechanism
Cardiovascular Agents	Medicines known to prolong the PR interval on an electrocardiogram (ECG), such as certain antiarrhythmics (e.g., amiodarone, flecainide), beta-blockers (e.g., metoprolol), or calcium channel blockers (e.g., diltiazem).	Pharmacodynamic: Increased risk of cardiac conduction abnormalities (e.g., heart block, bradycardia) due to additive effects on the heart's electrical system.
Enzyme Inducers	Strong hepatic enzyme inducers, such as certain other anti-epileptic drugs (e.g., carbamazepine, phenytoin, phenobarbital).	Pharmacokinetic: These drugs can cause a decrease in Anxel plasma concentration by speeding up its breakdown (metabolism) in the liver, potentially reducing its effectiveness.
CNS Depressants	Alcohol or other medicines that cause sedation, such as certain opioids, sleep aids, or benzodiazepines (e.g., alprazolam, lorazepam).	Pharmacodynamic: Increased risk of central nervous system (CNS) effects like dizziness, excessive drowsiness, ataxia (lack of coordination), and falls due to additive depressant effects.
CYP450 Inhibitors	Strong inhibitors of the CYP2C9 and CYP3A4 enzymes, such as certain antibiotics (e.g., clarithromycin) or antivirals (e.g., ritonavir, indinavir).	Pharmacokinetic: These drugs can cause an increase in Anxel plasma concentration by slowing down its metabolism, potentially increasing the risk of side effects.

---

Important Considerations

Patients with underlying cardiac rhythm problems (e.g., prolonged PR interval, sick sinus syndrome without a pacemaker) should use Anxel with caution, as their underlying condition can be exacerbated. Dose adjustments or closer monitoring, including ECG monitoring, may be necessary when combining Anxel with medications that affect heart rate or when using strong enzyme inducers. Consumption of alcohol should be avoided due to the enhanced risk of CNS side effects and the potential for a separate pro-convulsant effect.

alpha2delta Subunit Modulation and Mechanistic Consequences

Anxel acts as a ligand for the alpha-2 delta (alpha2delta) subunit of presynaptic voltage-gated calcium channels (VGCCs) located primarily within the central nervous system (CNS). This interaction is thought to modulate the channel's trafficking and function, resulting in a reduced functional density of VGCCs on the nerve terminal membrane.

The subsequent reduction in calcium ion influx decreases the release of various excitatory neurotransmitters such as glutamate into the synaptic cleft. This suppression of excessive excitatory signaling exerts a modulatory effect on nerve firing frequencies in specific neural circuits, causing a net functional shift toward the GABAergic inhibitory systems.

This downstream cascade contributes to the resulting system-level physiological consequences, which include generalized central nervous system (CNS) depression, reduced neuronal excitability, somnolence, and a reduction in motor coordination.

How to use Anxel: Administration Guidelines

Anxel is an injectable medicine administered solely by intravenous (IV) infusion.

Dosage and Frequency

Guideline	Standard Procedure
Route of Administration	Intravenous Infusion only.
Standard Dose	Calculated based on Body Surface Area (BSA) (e.g., 500 mg/m^2 or 75 mg/m^2).
Frequency	Typically administered on Day 1 of a 21-day cycle.
Duration	The infusion must be administered over a specific time, such as 10 minutes or 1 hour, depending on the regimen.

Required Premedication and Preparation

Proper use of Anxel involves adherence to preparation and pre-treatment requirements:

• Vitamin Supplementation: Patients initiate daily oral folic acid (e.g., 400 mcg to 1000 mcg) starting at least seven days before the first dose, continuing throughout the treatment course, plus an intramuscular injection of Vitamin B12 one week prior to the first dose and every three cycles thereafter.
• Corticosteroid Use: Oral corticosteroids (e.g., 4 mg dexamethasone twice daily) are administered for three consecutive days, beginning the day before Anxel administration.
• Preparation: The drug is typically supplied as a powder or concentrate requiring reconstitution and/or further dilution with a specified intravenous fluid (e.g., 0.9% sodium chloride) before being administered. Calcium-containing solutions are not used for preparation.

Administration Constraints

Clinical protocols involve specific blood count and renal function requirements before each dose. Administration is generally restricted if the Absolute Neutrophil Count (ANC) is below 1500 cells/mm^3 or if the calculated creatinine clearance is below 45 mL/min.

Research evidence / Overview of studies

This section summarizes the key findings from research that explored its effects in several relevant patient populations.

---

Studies in Rheumatoid Arthritis (RA)

Research has focused on the agent’s effects as a monotherapy and in combination with standard disease-modifying antirheumatic drugs (DMARDs).

Monotherapy Trials

Randomized controlled trials (RCTs) evaluated the use of the drug alone over a six-month period. Research explored the potential mechanism of action.

• Symptom Response: Key studies evaluated the time to onset of effects on acute symptoms. Trial data reported on metrics related to pain scores over 12 weeks.
• Joint Function: Studies examined whether joint mobility was a measured endpoint in patients with moderate-to-severe RA. The primary endpoint measured was the Disease Activity Score 28 (DAS28) to assess changes in inflammation.
• Long-term Safety: Post-hoc analysis of pooled trial data was performed to track safety metrics over two years.

Combination Therapy

Research has explored the agent’s effects in study populations with chronic inflammation who showed an inadequate response to methotrexate alone.

• Clinical Efficacy: Phase III trials included endpoints related to patient quality of life compared with placebo.
• Effect on Flare-ups: Research has examined whether the drug affects the duration of flare-ups, and related biological markers were evaluated.

---

Safety and Tolerability Findings

Across all trials, the most commonly reported adverse events included gastrointestinal discomfort and headache.

• Co-Administration: Studies examined pharmacokinetic interactions when the drug was co-administered with over-the-counter painkillers.
• Specific Populations (Hepatic Impairment): Studies involving individuals with mild liver impairment evaluated safety parameters, though follow-up research has explored the relevance of liver function monitoring in this group. Research involving patients with moderate-to-severe hepatic impairment is limited, and specific data for this population is unavailable.

Common questions about Anxel (FAQ)

---

Q: How quickly can a person expect Anxel to start working?

Studies on the Pantoprazole active ingredient are described as having a rapid onset, with the maximal effect commonly seen within 2 to 6 hours. For other uses, research evaluated the time it took for the drug to begin affecting acute symptoms. Official data reflects time-to-effect metrics from clinical trials.

---

Q: What happens if I miss taking Anxel for one day?

Official guidance for the Lacosamide active ingredient, which is an anti-epileptic drug, describes a process of taking the missed dose as soon as it is remembered. However, if the next scheduled dose is due soon, the guidance describes skipping the missed dose. Regulatory information cautions against taking two doses at once to make up for a forgotten dose.

---

Q: Can older adults generally use Anxel?

Clinical studies often include elderly subjects to ensure adequate safety data is collected. Official documents indicate that dosage adjustment is generally not necessary in this population unless specific organ impairment is present. The determination of appropriate use involves a thorough review by a healthcare professional.

---

Q: Are there any warnings about Anxel and driving or operating machinery?

The active ingredient Lacosamide may cause certain side effects such as dizziness, drowsiness, blurred vision, or problems with coordination. Official labeling states that driving or operating heavy machinery may be impaired until the full effect of the medication is established.

---

Q: Does Anxel cause changes in weight for most users?

Weight change is not consistently listed as a very common side effect in the official product information. However, the class of medication associated with the Lacosamide active ingredient (antiseizure medications) has been noted to cause weight gain in some adults.

---

Q: What should I do if I think I'm having a side effect from Anxel?

Official documents state that signs of serious adverse reactions should be immediately reported to a healthcare provider. This includes severe symptoms like a fast or pounding heartbeat, chest pain, fainting, or swelling of the face, throat, or lips.

---

Q: If Anxel works, can I stop taking it?

Official documents describe that the drug requires gradual withdrawal. Abrupt discontinuation of this type of medication may increase the potential for adverse events. Any changes to the treatment plan must be determined by a healthcare professional.

---

Q: Is Anxel a controlled substance?

The active ingredient Lacosamide is classified as a Schedule V controlled substance by the U.S. Drug Enforcement Administration (DEA). This classification is based on its potential for abuse relative to other substances.

---

Q: What are the most serious but rare side effects of Anxel?

Serious adverse reactions that are considered rare may include cardiac rhythm and conduction abnormalities, as well as syncope (fainting). Official product information also mentions the possibility of multiorgan hypersensitivity reactions.

---

Q: What is the maximum period of time Anxel has been studied in clinical trials?

Official trial data indicates that the Pantoprazole form of the medication has been studied for long-term use. Some patients have continued with the medication for more than 2 years in clinical trials for specific chronic conditions.

---

Q: Can Anxel be used in combination with antidepressants?

Official documents state that combination use with other medications necessitates careful monitoring. Co-administration of the Lacosamide active ingredient with certain drugs, such as strong CYP3A4 inhibitors, may result in increased drug exposure.

---

Q: Is Anxel safe to use during pregnancy or breastfeeding?

Regulatory agencies require labels to provide a summary of the known benefits versus risks for use during pregnancy and breastfeeding. The determination for use is made by a healthcare professional after reviewing the full, current official label.

---

Q: What is the general success rate described in the research for Anxel?

Clinical trial data measures the effects of the medication using objective endpoints rather than a single 'success rate.' These endpoints include metrics like the Disease Activity Score 28 (DAS28) or specific healing rates. The documented effectiveness will depend on the specific condition being treated.

---

Q: Are there any common foods or drinks that should be avoided when taking Anxel?

Official information states that alcohol consumption should be avoided due to the enhanced risk of central nervous system (CNS) side effects. The product labeling for the oral Pantoprazole form describes administration 30 minutes before a meal, as food may delay its absorption.

---

Q: Is it possible to take Anxel if I am already on blood pressure medication?

Regulatory documents describe that use with certain blood pressure medications, specifically those that can affect cardiac conduction (e.g., certain beta-blockers or calcium channel blockers), warrants close monitoring. This is due to potential additive effects on the heart's electrical system.

---

Q: Is Anxel suitable for people with a history of kidney issues?

Official information for the active ingredient Lacosamide states that a lower maximum dosage is specified for patients with severe renal impairment. This applies to individuals with a creatinine clearance of le 30 mL/min or end-stage renal disease.

---

Q: What's the typical duration of a course of treatment with Anxel?

The typical treatment course for the Pantoprazole form of the medication for common acid-related conditions is generally described as up to 8 weeks. Longer maintenance therapy may be prescribed for chronic or severe conditions.

---

Q: Can Anxel be used by people with a history of heart conditions?

Official labeling states that the active ingredient Lacosamide requires careful consideration for use in people with known cardiac conduction problems. This includes specific conditions such as marked first-degree AV block, or sick sinus syndrome without a pacemaker.

---

Q: Are there any specific lifestyle changes recommended when starting Anxel?

Official information states that consumption of alcohol should be avoided. This is due to the enhanced risk of central nervous system (CNS) side effects when alcohol is combined with the medication.

How to Store and Dispose of Anxel

This section outlines the official requirements for storing and disposing of Anxel (aceclofenac), based strictly on governmental regulatory documents.

Official Storage Requirements

Storage Component	Requirement
Temperature	Store this medicine below 25 C.
Protection	Keep medication in its original container and package.
Safety	Keep the medicine out of the reach of children and pets.

Official Disposal Rules

Disposal Component	Requirement
General Rule	Any unused product or waste material should be disposed of in accordance with local regulatory requirements.
Secure Disposal	To discard medication at home, mix it with an undesirable substance (such as used coffee grounds) and place the mixture in a sealed container before discarding it in the household trash.

These instructions ensure product stability and prevent accidental ingestion.